flupenthixol-decanoate and Basal-Ganglia-Diseases

We investigated as to whether dosedependent extrapyramidal tolerance of Flupentixol decanoate is inferior to that of Risperidone.. 143 Risperidone and 177 Flupentixol decanoate treated patients were consecutively entered into this non - randomized open study and assessed with the Simpson-Angus-Scale regarding presence of rigor. Treatment comparisons of rigor frequency was done by Kaplan-Meier analysis.. The risk of rigor increased with dose on both treatments. EPMS-risk was not increased under treatment with Flupentixol decanoate (mean dose 35.06 +/- 19.7 mg/2 weeks) compared to Risperidone (mean daily dose: 5.2 +/- 2.5 mg/kg) when comparable weight standardized Haloperidol equivalence doses (WHE) were used.. This study offers limited evidence for methodological reasons. Yet, results do not support the view that EPS are more frequent on Flupentixol decanoate than on Risperidone when doses are comparable.

Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Flupenthixol; Haloperidol; Humans; Incidence; Male; Middle Aged; Muscle Rigidity; Neurologic Examination; Prospective Studies; Risperidone

Topics: Adult; Basal Ganglia Diseases; Female; Fluoxetine; Flupenthixol; Humans; Neurologic Examination; Obsessive-Compulsive Disorder; Psychoses, Substance-Induced